HealthEquity's Q4 revenue beat estimates, but EPS missed. Raymond James upgraded the stock to Strong Buy, citing long-term growth despite fraud concerns.
Latest Ratings for HQY
Date | Firm | Action | From | To |
---|
Feb 2022 | Deutsche Bank | Maintains | | Buy |
Dec 2021 | JP Morgan | Maintains | | Overweight |
Dec 2021 | Deutsche Bank | Maintains | | Buy |
View More Analyst Ratings for HQY
View the Latest Analyst Ratings
read more